Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Disease area: Airway diseases

Abstract

Combination corticosteroid/long acting b₂ agonist (ICS/LABA) inhalers are widely used asthma treatments and an increasing number of preparations are now available. In Scotland, Health Board ICS/LABA recommendations are inconsistent. Such recommendations are based on clinical trial data. Fostair (beclometasone/formoterol) has been recommended by several Scottish Health Boards.Routine healthcare data were used to investigate asthma control and exacerbation rate after switching real-life asthma patients to Fostair.We linked Scottish national healthcare databases: The Prescribing Information System (PIS) of dispensed medications and the SMR01 hospital admission database. Asthma severity was defined by BTS/SIGN treatment step: control by short acting b₂ agonist (SABA) usage, exacerbations by short course prednisolone and/or hospitalisation with asthma. These were compared for the year before and after patients aged 5-45 were commenced on Fostair.For 2011-2013 we identified 312,285 patients in the PIS on medication for active asthma. 6,965 were commenced on Fostair during this time period. 1,339 patients were included in a 12 month before/after comparison. Comparing the 12 months before and after switching, Fostair use was not associated with any change in the number of exacerbations/y 0.318 vs 0.299 p=0.45, asthma hospitalisations/y 0.027 vs 0.026, p=0.92, short course prednisolone use/y 0.28 vs 0.26, p=0.47 or SABA doses/d 0.797 vs 0.757 p=0.47.In real-life, switching patients to Fostair is not associated with any change in asthma control or exacerbation rate. Further case/control analysis will be conducted to contextualise these results.


Rating:

Share or cite this content

Citations should be made in the following way:
Graham Devereux (Aberdeen, United Kingdom), Markus Steiner, Steve Turner, Graham Devereux. A national database study of the effectiveness of switching real-life asthma patients to fostair. Eur Respir J 2015; 46: Suppl. 59, 2954

Member's Comments

No comment yet.

Related content which might interest you: Prescription patterns and treatment adherence of asthma controller therapy in children in a Dutch primary care database Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Demographic, clinical and health care resource utilisation characterisation of patients prescribed omalizumab: A retrospective, real world data study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 An overview of patient adherence to asthma medication in Canada Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Asthma medication during pregnancy: A cohort study in EFEMERIS database Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Asthma severity, poor control, co-morbidities and prior resource use determined omalizumab prescriptions in a nested case-control study with US claims data Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms Year: 2015 LATE-BREAKING ABSTRACT: Effectiveness of individualized self management support for children with asthma in Dutch outpatient clinics, preliminary results of a randomized controlled trial. Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Effectiveness of montelukast on asthma control in infants: A claims data study Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Work related symptoms of adult patients with asthma: A multicenter, national, questionnaire based study Source: International Congress 2015 – Work, environment and the epidemiology of asthma Year: 2015 Asthma therapeutic management in the elderly: Pharmacoepidemiological approach in the E3N cohort Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Long term outcome of asthma in adults; study design and participation Source: International Congress 2014 – Epidemiology of asthma Year: 2014 Ownership of written asthma action plans in a large Australian survey Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013 Predicting asthma exacerbations in children – A real life observational study Source: International Congress 2015 – Highlights in paediatric epidemiology: air pollution, asthma and primary ciliary dyskinesia Year: 2015 REG study: Real-life, longitudinal ICS adherence patterns in a UK asthma population Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Mortality rates in individuals with asthma, COPD and ACOS in a large population-based cohort: Is gender important? Source: International Congress 2016 – Asthma, COPD, and ACOS: physical activity, dietary aspects, and diseases burden Year: 2016 Asthma management in a specialist setting: Results of a national survey Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 The Italian registry for severe/uncontrolled asthma Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life Year: 2016 Prevalence of asthma and management of exacerbations in general practice (GP) after computerised Spanish guideline on the management of asthma (GEMA) and collaborative care environment Source: International Congress 2015 – Management of asthma and COPD in primary care Year: 2015 Interim analysis of post-marketing surveillance of omalizumab in Japan Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Current and future costs of asthma in the Netherlands Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013